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ABSTRACT
Hepatorenal syndrome (HRS) is a serious complication of
end-stage liver disease, occurring mainly in patients with
advanced cirrhosis and ascites, who have marked
circulatory dysfunction,1 as well as in patients with acute
liver failure.2 In spite of its functional nature, HRS is
associated with a poor prognosis,3 4 and the only effective
treatment is liver transplantation.
During the 56th Meeting of the American Association for the
Study of Liver Diseases, the International Ascites Club held a
Focused Study Group (FSG) on HRS for the purpose of
reporting the results of an international workshop and to
reach a consensus on a new definition, criteria for diagnosis
and recommendations on HRS treatment. A similar
workshop was held in Chicago in 1994 in which
standardised nomenclature and diagnostic criteria for
refractory ascites and HRS were established.5 The
introduction of innovative treatments and improvements in
our understanding of the pathogenesis of HRS during the
previous decade led to an increasing need to undertake a
new consensus meeting. This paper reports the scientific
rationale behind the new definitions and recommendations.
The international workshop included four issues debated
by four panels of experts (see Acknowledgements). The
issues were: (1) evidence-based HRS pathogenesis; (2)
treatment of HRS using vasoconstrictors; (3) other HRS
treatments using transjugular intrahepatic portosystemic
stent-shunt (TIPS) and extracorporeal albumin dialysis
(ECAD); and (4) new definitions and diagnostic criteria for
HRS and recommendations for its treatment.
BACKGROUND
The definition and diagnostic criteria for HRS
established in 19945 were based on the following
three concepts:
1. renal failure in HRS is functional and caused by
marked intrarenal arteriolar vasoconstriction;
2. HRS occurs in patients with systemic circula-
tory dysfunction caused by extra-renal vasodi-
latation;
3. plasma volume expansion does not improve
renal failure.
Four new concepts have emerged since then,
these are:
a. Extra-renal arterial vasodilatation occurs
mainly in the splanchnic vascular bed, whereas
other vascular beds, such as those which
supply the brain and the liver, may be
vasoconstricted. This may contribute to the
development of hepatic encephalopathy and
hepatic failure, respectively.
b. Cardiac output in patients with HRS may be
low, normal or high, but it is insufficient for
the patient’s needs because of reduced periph-
eral resistances.
c. The most common trigger for the development
of type-1 HRS is bacterial infection, mainly
spontaneous bacterial peritonitis (SBP).
d. Renal function can be improved by medical
treatment in patients with HRS and is
associated with improved survival.
Background for the new concepts
The first of these concepts was formulated follow-
ing investigation conducted using Doppler ultra-
sonography or plethysmography both before and
after 1994. These studies were performed in
patients with varying degrees of severity of
cirrhosis, and revealed arterial vasodilatation in
the splanchnic circulation as well as arterial
vasoconstriction in other areas such as the brain,
kidneys and liver,6–13 whereas the cutaneous and
muscular blood flow has been reported as low,
normal or increased.13–16 The dilatation of the
splanchnic vessels is mainly caused by local release
of potent vasodilators such as nitric oxide (NO),17
which also render the splanchnic circulation
resistant to various vasopressors including angio-
tensin II, norepinephrine, vasopressin and endothe-
lin.18–24 The resistance of the splanchnic circulation
to these vasopressor agents renders the control of
arterial pressure in cirrhosis dependent on the
extra-splanchnic effects exerted by the endogenous
vasoconstrictor systems. As arterial vasodilatation
increases with progression of cirrhosis, the role of
vasoconstrictors in maintaining haemodynamic
stability becomes critical, and explains why cirrho-
tic patients with HRS are predisposed to develop
renal, hepatic and cerebral vasoconstriction.
The second new concept—that is, that insufficient
cardiac output contributes to renal hypoperfusion in
patients with HRS—was first suggested by Tristani
and Cohn,25 but it is only recently that this has been
confirmed.26 27 The first study showed that the
cardiac output of cirrhotic patients with SBP who
developed progressive renal failure was relatively low,
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despite resolution of infection, when compared with
a similar group of patients with SBP who did not
develop renal failure.26 The second study compared
non-azotaemic cirrhotic patients who developed
HRS with similar patients who did not, and showed
that low cardiac output and high plasma renin
activity (PRA) were independent predictors of HRS.27
Moreover, in patients developing HRS, the progres-
sion of circulatory dysfunction leading to arterial
hypotension and renal failure occurred in the setting
of a continued decrease in cardiac output and
increase in PRA. These findings support the hypoth-
esis that hyperdynamic circulation is essential to
maintain central blood volume and renal perfusion in
cirrhosis. Therefore, when cardiac output decreases,
effective hypovolaemia occurs, leading to renal
hypoperfusion and HRS. The mechanism leading to
impaired or insuffient cardiac output in patients
developing HRS is unknown. In recent years, a
specific cardiac abnormality, characterised by atte-
nuated systolic and diastolic responses to stimuli,
changes in repolarisation and hypertrophy of the
cardiac chambers, has become increasingly recog-
nised—the so-called ‘‘cirrhotic cardiomyopathy’’.28 A
fall in cardiac preload due to a decrease in venous
return is another hypothesis that might justify the
effectiveness of albumin infusion.27
HRS can be triggered by precipitating events.
The most important of these are infection, bleed-
ing and large-volume paracentesis without albu-
min administration.29–32 The role of SBP has
recently been emphasised. Table 1 compares the
results of two studies29 30 assessing the prevalence
of renal failure in cirrhotic patients with SBP and in
those with infections unrelated to SBP, and shows
that: (a) in spite of an effective antibiotic therapy,
a significant proportion of cirrhotic patients with
bacterial infection develop progressive renal failure.
This almost exclusively occurs in patients with
SBP; (b) in patients not responsive to antibiotic
therapy, progressive renal failure occurs and is
independent of the type of infection. Furthermore,
changes in circulatory function, endogenous
vasoactive systems and renal function in patients
developing renal failure triggered by SBP are
identical to those observed in patients with HRS
unrelated to infection, suggesting that the patho-
genesis of progressive renal failure in cirrhotic
patients with infection is the same as that of HRS.
The most important concept of HRS, however,
arises from studies exploring new therapeutic
strategies.33 Since type-1 HRS is often associated
with a rapid deterioration of liver function with
increased levels of bilirubin and prothrombin time, it
has traditionally been viewed as a manifestation of
terminal hepatic failure. The demonstration that
type-1 HRS can be improved by vasoconstrictors34 or
by TIPS,35 36 and that reversal of type-1 HRS may be
associated with improved survival, represents a
major change in our understanding of the syndrome.
In conclusion, the main pathogenic mechanism
in type-1 HRS is a potentially reversible deteriora-
tion of systemic circulatory function, mostly due
to splanchnic vasodilatation and renal vasocon-
striction and often triggered by a precipitating
event (fig 1). In addition to renal failure, the
syndrome may be associated with other organ
dysfunctions, such as decreased cardiac output,
hepatic failure and encephalopathy.
TREATMENT OF HRS
New treatments of HRS are designed to expand the
central blood volume by simultaneously increasing
the total plasma volume and reducing intense
peripheral vasodilatation. This strategy is not
entirely new, as in 1967 Tristani and Cohn25 showed
that dextran infusion improved cardiac output and
renal perfusion in oliguric cirrhotic patients, and 18
years later Shapiro et al37 showed that the urine
water and sodium excretion in cirrhotic patients
with ascites was improved by the administration of
norepinephrine combined with head-out water
immersion, a manoeuvre aimed at expanding central
blood volume. However, clinically relevant results
have only been obtained more recently with the use
of albumin and various vasoconstrictors.
The mechanism by which vasoconstrictors and
albumin improve the glomerular filtration rate
Main pathophysiological and clinical aspects of HRS
c HRS is a functional renal failure caused by intrarenal vasoconstriction which
occurs in patiens with end-stage liver disease and circulatory dysfunction.
c Circulatory dysfunction is characterised by vasodilatation in the splanchnic
circulation with a relatively low and insufficient cardiac output, leading to
effective hypovolaemia.
c HRS may occur spontaneously with worsening liver function, or secondary to
a precipitating event such as bacterial infection (eg, SBP).
c HRS can be improved by the administration of vasoconstrictors and albumin,
or by TIPS.
Table 1 Incidence and course of renal failure in cirrhotic patients with severe bacterial infections without shock
according to response to antibiotic treatment and to type of infection
No response Response
SBP (n = 21)*
Sepsis unrelated to SBP
(n = 9){ SBP (n = 231)*
Sepsis unrelated to SBP
(n = 98){
No renal failure 3 (14%) 2 (22%) 166 (71%) 77 (78%)
Transient renal failure 0 (0%) 0 (0%) 21 (9%) 22 (22%)
Steady renal failure 1 (5%) 2 (22%) 26 (11%) 0 (0%)
Progressive renal failure 17 (81%) 5 (55%) 18 (7%) 1 (1%)
*Data on spontaneous bacterial peritonitis (SBP) are from Follo et al.29
{Data on sepsis unrelated to SBP are from Terra et al.30
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(GFR) in patients with HRS is incompletely
understood. Nevertheless, administration of terli-
pressin to patients with HRS increases blood
pressure and leads to a significant decrease in
PRA and increase in GFR,38 indirectly indicating
correction of circulatory dysfunction. It is con-
ceivable that vasopressin analogues cause vasocon-
striction of the splanchnic bed, thereby allowing
redistribution of the blood volume to some of the
extrasplanchnic organs including the central com-
partment and the kidneys. Filling of the central
compartment will lead to the inhibition of the
sympathetic nervous and renin–angiotensin sys-
tems, thereby shifting the autoregulatory curve to
the left and making renal blood flow and GFR
more responsive to changes in blood pressure.39 40
Albumin is traditionally considered to improve
circulatory function in cirrhosis by expanding
central blood volume and increasing cardiac out-
put.41 Moreover, recent studies have shown that
the administration of albumin to cirrhotic patients
with SBP causes arterial vasoconstriction and blood
pressure increase,42 probably attributable to the
ability of albumin to bind vasodilators. It is
therefore conceivable that an improvement of
renal function in patients with HRS treated with
vasoconstrictors and albumin is due to the additive
effects that the two compounds have on cardiac
function and peripheral arterial circulation.
Prophylaxis of HRS
One randornised controlled trial (RCT) showed that
albumin prevented type-1 HRS in patients with SBP.41
Patients receiving albumin (1.5 g/kg body weight on
the first day plus 1 g/kg body weight on the third day)
showed a 66% reduction in the incidence of HRS (10%
vs 33%) and a significant reduction of in-hospital and
3-month mortality rates (10% vs 29%, p,0.01, and
22% vs 41%, p,0.03, respectively,). The albumin
effect was related to an improvement in systemic
haemodynamics, as indicated by PRA suppression.
Indeed, albumin infusion in cirrhotic patients with
SBP improves both cardiac function and systemic
vascular resistance.43 As type-1 HRS almost exclu-
sively occurred in patients with serum bilirubin
.68 mmol/l (4 mg/dl) and serum creatinine
.88.4 mmol/l (1 mg/dl), the prophylactic use of
albumincouldprobablybe restrictedtothese patients,
but trials need to be conducted so that the optimum
dosage to be used can be defined more precisely.
New treatments of HRS
Vasoconstrictors and albumin
The use of an analogue of vasopressin to improve
renal blood flow in cirrhotic patients was first
proposed by Kew et al 35 years ago.44 More
recently, Lenz et al45 showed that GFR may be
moderately improved by ornipressin infusion in
patients with HRS, but the drug was given for only
4 h, therefore precluding assessment of its long-
term effects. Two more studies demonstrated that
a long-term (1–2 weeks) infusion of ornipressin,
combined with albumin or dopamine, normalised
serum creatinine concentrations in many patients
with type-1 HRS.34 46 Interestingly, recurrence of
renal failure rarely occurred after treatment with-
drawal, and in the few cases where it did recur a
second course of therapy was successful. However,
the drawback with ornipressin was the frequent
occurrence of ischaemic complications.34 46
Therefore, widespread use of vasoconstrictors in
patients with HRS has only become clinically
feasible with the advent of safer compounds such
as terlipressin,47–49 a vasopressin analogue with longer
activity, and the a2-agonist midodrine combined
with octreotide.50 51 Table 2 summarises the data
available on the use of terlipressin in type-1 HRS.
Figure 1 Schematic view of the
pathogenetic mechanisms of hepatorenal
syndrome in cirrhosis. Dotted arrows
indicate that precipitating factors are
frequent but not necessary. RAAS, renin–
angiotensin–aldosterone system; SBP,
spontaneous bacterial peritonitis; SNS,
sympathetic nervous system.
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They include four RCTs,38 48 52 53 and many pilot or
retrospective studies.
These studies show that: (a) although GFR rarely
reaches normal levels, a short period of treatment
with terlipressin improves renal function in up to
65% of patients with type-1 HRS; (b) the effective-
ness of terlipressin is probably enhanced by albu-
min;49 (c) HRS recurs after treatment withdrawal in
approximately 20% of patients, but re-treatment is
often effective; (d) in most cases, dilutional hypona-
traemia associated with HRS improves with terli-
pressin treatment;48 49 (e) severe side effects of the
treatment are uncommon (5–10%). With regards to
survival, patients who experienced a complete
reversal of type-1 HRS by terlipressin seem to have
improved short-term survival, although the RCT of
Sanyal53 reported similar survival at 60 days of
follow-up between patients treated with terlipressin
plus albumin and those treated only with albumin.
Therefore, the long-term survival of patients with
type-1 HRS treated with terlipressin merits further
investigation. Nevertheless, using terlipressin to
improve renal function is an important support
resource for patients included on a liver transplant
waiting list who develop type-1 HRS.54
The initial dose of terlipressin in many studies
ranged from 0.5 to 1 mg every 4–6 h. This regimen
was maintained until reversal of HRS, which
usually occurred within the second week of
treatment.47 52 In other studies, the initial dose in
cases without an early response was increased up
to 2 mg every 4–6 h.49 The daily dose of albumin
was generally 20–40 g, preceded in some studies by
a load of 1 g/kg body weight. Some refer to central
venous pressure to establish and titrate albumin
doses and to prevent fluid overload.
Experience of using midodrine in patients with
type-1 HRS is more limited. To date, there have
been two pilot studies.50 51 In both, midodrine was
combined with octreotide to enhance the effect of
splanchnic vasoconstriction, but doses and routes
of administration were quite different. Angeli et al50
used 7.5–12.5 mg of oral or intravenous midodrine
three times a day plus 100–200 mg of subcutaneous
octreotide three times a day, whereas Wong et al51
used 2.5 mg of oral midodrine three times a day
plus an intravenous infusion of octreotide (25 mg/h
after a bolus of 25 mg). The dose of midodrine was
adjusted to increase mean arterial pressure to
90 mm Hg. Albumin was also administered to
patients in these studies. The results are similar to
those observed with terlipressin, although the
response was slower. Since octreotide alone had
no impact on GFR in patients with HRS,55 it is
likely that midodrine plays the main role in
improving GFR.
A pilot study has also explored the effect of
norepinephrine infusion (0.5–3 mg/h) combined
with albumin and furosemide in type-1 HRS.56
The doses were titrated to increase mean arterial
pressure by 10 mm Hg. Reversal of HRS was
achieved in 10 out of 12 cases and was associated
with improvement in urinary sodium excretion
and decrease in PRA. Norepinephrine is cheaper
and more widely available than terlipressin, but it
is thought to have a greater propensity to induce
cardiac arrhythmias. Therefore, the role of norepi-
nephrine in patients with type-1 HRS still needs to
be established on the basis of future comparisons
with terlipressin or midodrine/octreotide.
Only a few patients with type-2 HRS have been
specifically treated using terlipressin and albu-
min.33 In most cases, normalisation of serum
creatinine was observed, but, in contrast to type-
1 HRS, renal failure invariably recurred after
treatment withdrawal.
Table 2 Characteristics and results of studies reporting the effect of terlipressin in patients with cirrhosis and type-1
HRS
Author, year
(reference)
Type of
study
Success rate of
therapy{ Dose (mg/day) Duration (days)
Survival at
4 weeks* Adverse events
Ganne-Carrie, 199677 C 1/1 2 67 Yes Yes
Le Moine, 199878 C 1/1 6 30 Yes No
Duhamel, 200079 R 6/12 2–6 3–10 9/18 4/12
Colle, 200280 R 11/18 2.8 (0.1) 9 (1) 1/16 0/18
Halimi, 200281 R 12/16 1.5–12 2–16 3/7 4/16
Moreau, 200247 R 53/99 3.2 (1.2) 11 (12) 37/99 23/99
Danalioglu, 200382 R 3/7 2–4 3–14 ND No
Uriz, 200048 PU 4/6 3–6 5–15 4/6 1/6
Mulkay, 200183 PU 12/12 1–6 8–14 3/12 4/12
Angeli, 200684 PU 12/19 2–12 (15 13/19 ND
Ortega, 200249 PU T+A:8/9 2 4–14 8/9 1/16
T: 1/7 1/7
Hadengue, 199838 RCT 6/9 2 2 ND 0/9
Solanki, 200352 RCT T: 5/12 2 14 nd 5/12
P: 0/12
Sanyal, 200653 RCT T+A: 19/56 4–8 14 27/56{
A: 7/56 27/56{
Total 154/284 2–12 3–67 108/251 43/209
C, case report; R, retrospective; PU, prospective uncontrolled; PC, prospective controlled; RCT, randomised controlled trial; ND, not determined.
*Success rate of therapy means partial or complete response in terms of renal function. T+A, terlipressin+albumin; T, terlipressin; P, placebo; A, albumin.
{Survival was reported at 60 days.
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Transjugular intrahepatic portosystemic stent-shunt
Only a few studies have assessed the role of TIPS in
HRS—91 patients in total. Most were prospective
but uncontrolled studies.35 36 51 57 58 Three were
performed in patients with type-1 HRS,35 36 51 one
in patients with type-1 or type-2 HRS,57 and the
last specifically investigated type-2 HRS.58 The
following can be observed:
a. significant suppression of the endogenous
vasoactive systems, particularly the renin-
angiotensin system,35 and a decrease of creati-
nine levels were recorded after TIPS in most
patients with type-1 HRS. The rate of the
creatinine decrease was slower than is usually
obtained using terlipressin plus albumin;
b. recurrence of HRS was rare, provided that
there was no shunt malfunction;
c. hepatic encephalopathy was a frequent com-
plication of TIPS but was adequately managed
by medical treatment;
d. TIPS almost always induced a reduction of
ascites volume;
e. resolution of type-1 HRS by TIPS can improve
survival;
f. sequential treatment with vasoconstrictors
and albumin followed by TIPS could be used
as an alternative approach to increasing the
probability of long-term success;51
g. although TIPS may improve renal function and
refractory ascites in patients with type-2 HRS,
its effect on survival is still undefined.
However, since almost all studies excluded
patients with a history of severe encephalopathy,
serum bilirubin levels .85 mmol/l (5 mg/dl), or
Child-Pugh score .12, the applicability of TIPS
may be rather limited in patients with HRS who
frequently show jaundice, encephalopathy and
high Child-Pugh scores.59
There has been little investigation into the
mechanism through which TIPS exerts beneficial
effects in patients with HRS. Nevertheless, as TIPS
functions as a side-to-side portocaval shunt, it is
expected to relieve portal hypertension, which plays
a pivotal role in the pathogenesis of splanchnic
arterial vasodilatation.60 Moreover, TIPS insertion is
associated with an increase in cardiac output and an
expansion in central blood volume.61 62 The simulta-
neous effects on the splanchnic and systemic
circulation may represent the mechanism by which
TIPS improves renal perfusion, GFR, urine sodium
and water excretion, and hyponatraemia.63
Extracorporeal albumin dialysis (ECAD)
This procedure uses a cell-free albumin-containing
dialysate that is re-circulated and perfused through
charcoal and anion exchange columns (molecular
adsorbent recycling system (MARS)). The system
is also connected to a haemodialysis or haemoper-
fusion apparatus. ECAD enables the removal of
albumin-bound substances, including bilirubin, bile
acids, aromatic amino acids, medium chain fatty
acids and cytokines.64 There are few data available
for ECAD in cirrhotic patients with HRS, and these
data are controversial.65 66 ECAD decreases serum
creatinine levels, but it is not definitively known
whether or not this effect is due to a true
improvement of renal function or simply to the
filtration process. A few studies reported that
systemic haemodynamics improved during ECAD,
indicated by an increase in arterial pressure and
systemic vascular resistances, and a decrease in
cardiac output, PRA and norepinephrine levels.
However, studies regarding the effect of ECAD on
survival in patients with type-1 HRS included too
few patients to draw any definite conclusions.66 67
Moreover, ECAD is a very expensive procedure and
should still therefore be considered experimental.
Liver transplantation in patients with HRS
Liver transplantation was the only effective ther-
apy for patients with HRS before the introduction
of vasoconstrictors and TIPS, and is still the
treatment of choice for these patients.68–71 Further
impairment in GFR may be observed immediately
after liver transplantation, and many patients
require long-term dialysis (35% of transplanted
patients with HRS vs 5% of transplanted patients
without HRS).68 71 As calcineurin inhibitors (ciclos-
porin and tacrolimus) may contribute to GFR
impairment, it is suggested to delay their admin-
istration until a partial recovery of renal function is
recorded, usually 48–72 h after transplantation.
After this early impairment, GFR starts to improve
until an average value of 30–40 ml/min is reached
1–2 months postoperatively. This moderate renal
failure persists during the follow-up and is prob-
ably due to an enhanced nephrotoxic effect of
calcineurin inhibitors in patients with pretrans-
plant renal impairment. In fact, the haemodynamic
and neurohormonal abnormalities associated with
HRS disappear within the first month after
transplantation, and the patients regain their
ability to excrete sodium and free water.72
Patients with HRS who undergo liver transplan-
tation tend to have more complications, spend
more days in intensive care units and have higher
in-hospital mortality rates than liver transplant
patients without HRS.73 74 However, their 3-year
probability of survival is acceptable (60% vs 70–
80% in liver transplant patients without HRS).70
The main limitation of liver transplantation is
that due to the shortage of donor organs, and their
extremely short survival, most patients with type-1
HRS die before transplantation. The introduction of
the model of end-stage liver disease (MELD) for
organ prioritisation has partially solved this problem,
since patients with HRS are generally given high
priority on the waiting list. On the other hand,
treatment of type-1 HRS with vasoconstrictors and
albumin (see above) can improve patient survival,
and therefore improve their probability of being
transplanted. In one non-randomised pilot study,
reversal of type-1 HRS using terlipressin and
albumin was associated with reduction in early
morbidity and mortality after liver transplantation.54
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CONCLUSIONS OF THE CONSENSUS WORKSHOP
Improved knowledge of the mechanisms under-
lying HRS and the development of new treatment
strategies are the reasons for the new consensus on
definition, diagnostic criteria and HRS treatment
modalities organised by the International Ascites
Club.
New definition of HRS
HRS is a potentially reversible syndrome that
occurs in patients with cirrhosis, ascites and liver
failure, as well as in patients with acute liver failure
or alcoholic hepatitis. It is characterised by
impaired renal function, marked alterations in
cardiovascular function and overactivity of the
sympathetic nervous and renin–angiotensin sys-
tems. Severe renal vasoconstriction leads to a
decrease of GFR. There are two types of HRS.
Type-2 HRS is characterised by moderate renal
failure (serum creatinine from 133 to 226 mmol/l or
from 1.5 to 2.5 mg/dl), with a steady or slowly
progressive course. It appears spontaneously, but
can also follow a precipitating event. Type-2 HRS
is typically associated with refractory ascites.
Survival of patients with type-2 HRS is shorter
than that of non-azotaemic cirrhotic patients with
ascites but better than that of patients with type-1
HRS (fig 2).75
Type-1 HRS is characterised by rapid progressive
renal failure defined by doubling of the initial
serum creatinine concentrations to a level greater
than 226 mmol/l (2.5 mg/dl) in less than 2 weeks.
It may appear spontaneously, but often develops
after a precipitating event, particularly SBP. Type-1
HRS usually occurs within the setting of an acute
deterioration of circulatory function characterised
by arterial hypotension and activation of endogen-
ous vasoconstrictor systems, and may be associated
with impaired cardiac and liver functions as well as
encephalopathy. The natural prognosis of type-1
HRS is very poor (fig 2).
The main differences from the definition
reported in 19965 are:
a. the potential reversibility of HRS without liver
transplantation;
b. the dominant role of the splanchnic bed in
arterial vasodilatation;
c. the frequent role of SBP as an event precipitat-
ing type-1 HRS;
d. the concept that in addition to renal failure the
function of other organs, particularly the
heart, is frequently impaired.
Revised diagnostic criteria of HRS
As there are no specific hallmarks of HRS, the
diagnosis is based on the exclusion of other types
of renal failure. The criteria necessary to diagnose
HRS are reported in the box below.
The main differences between these criteria and
those previously established5 are:
a. creatinine clearance has been excluded because
it is more complicated than simple serum
creatinine for routine purposes, and it does
not increase the accuracy of renal function
estimation in cirrhotic patients;76
b. renal failure in the setting of ongoing bacterial
infection, but in the absence of septic shock, is
now considered HRS. This means treatment of
HRS can be started without waiting for
complete recovery from the infection;
c. plasma volume expansion should be performed
with albumin rather than saline. Members of
the panel agreed that albumin causes a greater
and more sustained expansion than saline;
d. minor diagnostic criteria have been removed as
they are not essential.
Treatments of HRS
Most data currently available on HRS treatments
come from retrospective analyses, pilot studies,
non-randomised comparative studies and only a
Effective treatments of type-1 HRS
c Albumin infusion may prevent HRS in patients with SBP.
c Vasoconstrictors and albumin are recommended as the first line of treatment
for type-1 HRS. Terlipressin is the most widely used vasoconstrictor.
Midodrine+octreotide and norepinephrine are two possible alternatives
requiring further clinical evaluation.
c With the use of terlipressin (2–12 mg/day) and albumin (20–40 g/day after
1 g/kg on the first day), about 60% of renal failure cases recover. The
improvement of survival using only vasoconstrictors and albumin seems
rather limited.
c TIPS is an alternative treatment in suitable patients, especially in those who
do not show a complete response to vasoconstrictors, but it can also be used
in patients who show a complete serum creatinine response to eliminate
ascites and to maintain normal renal function.
c Liver transplantation is the only treatment that assures long-term survival.
c Pharmacological treatment and TIPS can bridge the time to liver
transplantation and improve post-transplant survival.
Figure 2 Actuarial probability to survive in cirrhotic patients with different renal
impairments: non-azotaemic patients (continuous line); patients with hepatic renal
syndrome (HRS) type-2 (dotted line) and patients with HRS type-1 (red line). Adapted
from Alessandria et al.75
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few RCTs. Furthermore, most studies have
included too few patients. Therefore, concepts
and practical recommendations given in this part
of the article are based on both published data and
the personal experience of the panelists, and may
be improved upon by further experience gained in
the future.
Prevention of HRS
The incidence of HRS in patients with SBP may be
reduced by albumin administration, prevention
which was associated with improved survival.
The suggested dose of albumin is 1.5 g/kg body
weight on the first day and 1 g/kg body weight on
the third day, up to a maximum of 150 and 100 g,
respectively. Albumin administration is clearly
indicated for patients with SBP and serum bilirubin
levels .68.4 mmol/l (4 mg/dl) or serum creatinine
levels .88.4 mmol/l (1 mg/dl). Future studies are
necessary to define better optimal doses of albumin
and the subgroup of patients for whom treatment
is highly indicated.
Effective treatments of HRS
Liver transplantation
This is the treatment of choice for both type-1 and
type-2 HRS. Morbidity after liver transplantation
is higher in patients with HRS than in those
without HRS,74 although the long-term probability
of survival is only slightly lower. Reversal of type-1
HRS by pharmacological treatment before liver
transplantation may improve survival after trans-
plantation. The reduction in serum creatinine
levels after treatment and the related decrease in
the MELD score should not change the decision to
perform liver transplantation since the prognosis
after recovering from type-1 HRS is still very poor.
Pharmacological treatment with vasoconstrictors
Studies on the pharmacological treatment of HRS
have mainly been performed in patients with type-
1 HRS. Terlipressin is the most widely studied
compound. It should be started at 0.5–1 mg every
4–6 h. If there is no early response (.25% decrease
in creatinine levels after 2 days), the dose can be
doubled every 2 days up to a maximum of 12 mg/
day. Treatment can be stopped if serum creatinine
does not decrease by at least 50% after 7 days of
the highest dose, or if there is no reduction after
the first 3 days. In patients with early response,
treatment should be extended until reversal of HRS
(see text box) or for a maximum of 14 days.
Terlipressin may induce ischaemic side effects and
arrhythmias requiring drug discontinuation.33
Other vasoconstrictors tested in HRS are mido-
drine, in combination with octreotide, or norepi-
nephrine. The schedules for midodrine and octreotide
and those of norepinephrine are reported above.
In addition to creatinine levels being useful in
adjusting the doses of these vasoconstrictors, blood
pressure, renal water and sodium excretion, and
serum sodium levels may also be helpful.
The administration of albumin may improve the
effect of vasoconstrictors. In the absence of dose/
effect studies, the dose of albumin recommended is
1 g/kg of body weight on the first day, up to a
maximum of 100 g, followed by 20–40 g/day.
Albumin may be discontinued if serum albumin
concentration is .45 g/l and should be withdrawn
in the case of pulmonary oedema. Since this
complication is uncommon, catheterisation to
monitor central venous pressure is not mandatory,
but careful physical and radiological monitoring of
the cardiopulmonary function is recommended.
As reported in the text box, three types of
response to treatment with vasoconstrictors and
albumin can be observed. Complete response
occurs in approximately 60% of patients treated
with terlipressin and can improve survival. Renal
failure may recur after discontinuation of therapy
(relapse), but retreatment is usually effective. In
contrast, partial response is frequently followed by
a severe and irreversible relapse of renal failure.
TIPS
The small amount of data on the use of TIPS in
HRS shows that it improves renal function and
eliminates ascites. In patients with type-1 HRS,
TIPS may also improve survival, but this is
debatable in patients with type-2 HRS. The major
disadvantage of TIPS is its low applicability.
Indeed, it should not be used in patients with
serum bilirubin levels .85.5 mmol/l (5 mg/dl),
severe encephalopathy or history of recurrent
encephalopathy, severe bacterial infection, serious
cardiac or pulmonary dysfunction or a Child-Pugh
score .11.
New diagnostic hepatorenal syndrome criteria in cirrhosis
c Cirrhosis with ascites.
c Serum creatinine .133 mmol/l (1.5 mg/dl).
c No improvement of serum creatinine (decrease to a level of ( 133 mmol/l)
after at least 2 days with diuretic withdrawal and volume expansion with
albumin. The recommended dose of albumin is 1 g/kg of body weight per day
up to a maximum of 100 g/day.
c Absence of shock.
c No current or recent treatment with nephrotoxic drugs.
c Absence of parenchymal kidney disease as indicated by proteinuria
.500 mg/day, microhaematuria (.50 red blood cells per high power field)
and/or abnormal renal ultrasonography.
Types of response to treatment using vasoconstrictors
c Complete response (reversal of HRS); decrease of serum creatinine to below
133 mmol/l (1.5 mg/dl).
c Relapse of HRS: recurrence of renal failure (creatinine .133 mmol/l (1.5 mg/
dl)) after discontinuation of therapy.
c Partial response: decrease in serum creatinine to >50% of its pre-treatment
value, without reaching a level below 133 mmol/l (1.5 mg/dl).
c No response: no decrease of serum creatinine or decrease to,50% of its pre-
treatment value, with a final level above 133 mmol/l (1.5 mg/dl).
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Final recommendations for the treatment of
patients with HRS
Type-1 HRS
The first line of therapy is the use of vasoconstrictors
combined with albumin. Patients with partial or no
response to vasoconstrictors may be treated with
TIPS. If there are contra-indications to TIPS, ECAD
could be used in the setting of prospective trials.
The sequential use of vasoconstrictors plus
albumin and TIPS in suitable patients is an
interesting idea deserving further investigation.
Type-2 HRS
There are no definite data to support the use of
vasoconstrictors in these patients. TIPS can be used
to improve refractory ascites, which is often
associated with type-2 HRS. Data on the effect
of TIPS on survival are still insufficient.
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